Phathom Pharmaceuticals
Florham Park, NJ - One molecule, three indications, a single conviction: heartburn deserved better than the chemistry of 1989. This is the company that made acid blocking new again.
Florham Park, NJ - One molecule, three indications, a single conviction: heartburn deserved better than the chemistry of 1989. This is the company that made acid blocking new again.
Somewhere right now, a pharmacist slides a white box across the counter. Inside is VOQUEZNA - and behind that single tablet sits a company that spent five years dragging acid-suppression science out of the 1980s and into a million American medicine cabinets.
For more than three decades, the proton pump inhibitor was the final word on stomach acid. Omeprazole. Nexium. Pantoprazole. Reliable, generic, cheap - and unchanged. The science settled, the patents expired, and the field went quiet. Heartburn, it seemed, had been solved as well as it was ever going to be.
Phathom Pharmaceuticals disagreed. Founded in 2019 as a joint bet by Japanese drugmaker Takeda and the venture firm Frazier Healthcare Partners, the company licensed exclusive rights to a molecule called vonoprazan for the United States, Europe and Canada. It was not a tweak of an old pill. It was a different mechanism entirely - a potassium-competitive acid blocker, or P-CAB, a class that had been quietly used in Japan for years while America kept refilling its PPIs.
The pitch was almost stubbornly simple: take a drug that already worked elsewhere, prove it to the FDA, and give patients the first genuinely new acid-suppression option in over a generation. Stubborn pitches have a way of looking obvious only in hindsight.
The distinction sounds like alphabet soup until you understand the chemistry. A proton pump inhibitor has to be activated by stomach acid before it can work - which means it is slow, dose-dependent, and at its weakest when there is no food in the stomach. Vonoprazan skips that waiting room. As a potassium-competitive acid blocker, it sits on the acid pump directly and switches it off - faster, and more consistently across the day and night.
Approved for heartburn relief in non-erosive GERD and for healing and maintaining healing of erosive GERD in adults. The flagship - and the one in over a million prescriptions.
Vonoprazan co-packaged with amoxicillin and clarithromycin - a triple-therapy regimen built to eradicate H. pylori infection in adults.
A streamlined two-drug regimen of vonoprazan and amoxicillin - fewer pills, a regimen patients are likelier to finish.
A new branded drug is a slow fuse. Phathom lit it in 2023, watched 2024 build the base, and in 2025 revenue more than tripled to $175.1 million - a 217% jump - as prescriptions crossed 1.1 million. The company now projects operating profitability in 2026, with a $130 million public offering in January 2026 topping up the tank.
Phathom did not start in a garage. It started in a boardroom, with Takeda licensing out a proven asset and Frazier Healthcare Partners writing the founding check. The company opened with a $90 million crossover financing and a $50 million debt facility, then raised $181 million in its 2019 IPO under the ticker PHAT. Later, a revenue-interest agreement brought up to $260 million in non-dilutive capital to fund the launch without flooding the share count.
Its founding chairman was Dr. Tachi Yamada - a celebrated gastroenterologist who had led R&D at GlaxoSmithKline and run global health at the Gates Foundation. He died in August 2021, before the FDA approval he had bet on arrived. The company he helped start carried the bet across the line. In April 2025, Steven Basta - a 25-year biopharma and medical-device veteran - took over as President and CEO, succeeding Terrie Curran, who had led Phathom through launch.
Renowned GI physician-scientist; former GSK R&D chief and Gates Foundation global-health head. Founder, d. 2021.
25+ years across biopharma and medical devices; previously CEO of SaNOtize, Mahana, Menlo and Merz Aesthetics.
Takeda licensed vonoprazan; Frazier Healthcare Partners co-launched the company in 2019. NEA later joined as investor.
If you live with persistent heartburn, erosive GERD, or an H. pylori infection, VOQUEZNA is a prescription option your gastroenterologist or primary-care doctor can discuss - a different mechanism than the PPI you may have tried. For clinicians, the DUAL PAK and TRIPLE PAK package H. pylori eradication into regimens designed to be finished, not abandoned halfway. And for investors and industry watchers, Phathom (Nasdaq: PHAT) is a clean case study in single-asset commercialization: one molecule, three indications, a decade of exclusivity, and a launch curve bending toward profit.
The name itself is a quiet joke worth catching. A fathom measures depth. Phathom set out to plumb the depths of the GI tract - and, it turns out, the depth of a market everyone assumed was already mapped.